Gal-3 inhibition by GB0139 and TD139 compounds is under evaluation in idiopathic pulmonary fibrosis (IPF) [143,198,199], while MCP as a Gal-3 inhibitor has been considered for both hypertension and osteoarthritis [200,201]. This evidence concerns the gene LGALS3 and idiopathic pulmonary fibrosis.